Methods of preparing a nutritional product which contain a lipophilic nutrient are disclosed. The nutritional product is made using a fortifying powder containing the lipophilic nutrient a monoglyceride and diglyceride ("MDG") oil a phospholipid and a carrier. The fortifying powder enhances the digestive absorption ...

Disclosed are methods for identifying early-stage non- small - cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery that chromosomal copy number gains at Chrl9, 34.7 Mb - 35.6 Mb can be ...

Disclosed are nutritional compositions comprising a soluble viscous fiber and a polyphenol containing plant extract. The viscosity of the nutritional compositions may be adjusted and controlled without varying the concentration of the soluble viscous fiber in the composition by including the polyphenol containing pl...

Disclosed are 3",3"-N-bisdesmethyl-3",3"-N-bis-substituted-6-O-methyl-11-deoxy-11,12-cyclic carbamate erythromycin A derivatives of formula (I) which are antagonists of lutenizing hormone-releasing hormone (LHRH). Also disclosed are pharmaceutical compositions comprising the compounds, methods of using the compounds...

Disclosed are compounds of formula (I) which are useful for inhibiting neuraminidases from disease-causing microorganisms, especially, influenza neuraminidase. Also disclosed are compositions and methods for preventing and treating diseases caused by microorganisms having a neuraminidase, processes for preparing the...

Nutritional compositions that include calcium ?-hydroxy-?-methylbutyrate and protein, and methods of using and making the nutritional compositions are provided. Casein phosphopeptide is utilized to sequester the calcium ?-hydroxy- ?-methylbutyrate to reduce the interaction between the divalent calcium ions and prote...

Engineered multivalent and mulfispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease are provided.

A method of treating organic erectile dysfunction, particularly vasculogenic erectile dysfunction comprises administering to a male in need of such treatment a therapeutically effective amount of apomorphine or a pharmaceutically acceptable salt or pro-drug thereof.

A method for in vitro determination of the digestibility of proteins in a nutritional product. The method utilized gastric and intestinal enzymes that are standardized for in vitro digestion process that mimics the in vivo digestive process. Further, specificity in digestion is setermined by an amino acid profile. ...

A continuous process and system for manufacturing beta hydroxy beta methylbutyrate (HMB) and salts thereof is provided. The continuous process includes providing at least one oxidant and diacetone alcohol and combining the at least one oxidant with the diacetone alcohol in a first flow reactor to produce a product s...

The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which...

N/A

This invention discloses a novel method for the conversion of carboxylic acids to carbothioic acids and application of the method to the preparation of androstane carbothiolates, such as fluticasone propionate, which avoids column chromatography.

In one aspect, the invention relates to a process for preparing 6-O-substituted erythromycin derivatives comprising reacting 2'-substituted and optionally 4'-substituted 9-oxime erythromycin derivatives with an alkylating agent in the presence of a palladium catalyst and phosphine. In another aspect, the invention r...

Compounds having formula (I) are matric metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.

Compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein: V is selected from the group consisting of a covalent bond and CH2; W is selected from the group consisting of a covalent bond, CH2 and CH2CH2; X is selected from the group consisting of a covalent bond and CH2; Y is selected from the gr...

The instant invention provides novel macrolide compounds and compositions useful in treating bacterial infections. Also provided are processes for preparing same. These macrolides are substituted on the 6-O-position with X'-Y'-Z', wherein X' is selected from the group consisting of C1-C10 alkyl, C3-C10 alkenyl, and ...

Disclosed are methods of preparing dryblended powdered nutritional compositions including at least one dry ingredient that has undergone a microbial inactivation heat treatment sufficient to inactivate microbes present therein. The heat treatment comprises subjecting the dry ingredient to a temperature of greater th...

Heterocyclic substituted aminoazacyclic compounds of the formula (I): Z-R3, wherein Z is a defined aminoazacycle and R3 is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.

Compositions including an effective amount of each of phosphatidyl serine choline and oleic acid and methods for improving cognitive performance that include administering such compositions to a subject are described herein. The compositions can be nutritional compositions such as bars or liquids suitable for oral a...

The invention relates to a process for preparing quinoline-substituted carbonate and carbamate compounds, which are important intermediates in the synthesis of 6-O-substituted macrolide antibiotics. The process employs metal-catalyzed coupling reactions to provide a carbonate or carbamate of formula (I) or (II) or a...

Disclosed are methods of transforming a meal to improve the suitability of the meal for an individual with specific dietary needs that may be due to a medical condition. The methods include assessing the meal relative to the individual s dietary needs and administering a composition to the meal that tailors the meal...

The invention relates to compounds that are diazahomoadamantane derivatives, compositions comprising such compounds, and methods of using such compounds and compositions.

Disclosed herein is a nutritional composition having at least one protein at least one fat and at least one lipophilic compound the composition comprising at least one assembly comprising at least one hydrophobic protein monoglycerides and diglycerides ("MDG") and at least one lipophilic compound wherein at least 1%...

Disclosed herein is a nutritional composition having at least one protein at least one fat and at least one lipophilic compound the composition comprising at least one assembly comprising at least one hydrophobic protein monoglycerides and diglycerides ("MDG") and at least one lipophilic compound wherein at least 1%...

A process for the preparation of (2S, 3aR, 7aS)-octahydro-1H-indole-20carboxylic acid hydrochloride.

The present invention relates to engineered multivalent and multispecific binding proteins methods of making and specifically to their uses in the prevention diagnosis and/or treatment of disease.

Disclosed are compositions, including low-calorie beverages or liquids, comprising isoleucine, leucine, valine, cysteine, and methionine, in specified amounts, weight ratios, or both. The compositions are especially useful in treating individuals afflicted with impaired glucose tolerance or diabetes. ...

Disclosed are sterilized liquid protein supplements including extensively hydrolyzed casein for use with human milk and other infant feeding formulas. The sterilized liquid protein supplements have a low pH thereby inhibiting protein denaturation and reducing microbial growth.

Compositions for improving bone health joint health or both in an individual in need thereof are provided along with methods of using the compositions. Generally the compositions include a combination of Curcumin and Vitamin K2. The compositions may also include a protein a carbohydrate and a fat. The compositions a...

Disclosed herein are shelf -stable , clear liquid nutritional compositions having a pH ranging from 2.5 to 4.6 and comprising water; at least one source of EGCg in an amount sufficient to provide 200- 1700 mg/L of EGCg; and at least one source of protein in an amount sufficient to provide 25- 45 g/L of total protein...

Disclosed are nutritional products comprising pea protein hydrolysates as a primary or sole source of protein. The nutritional products include nutritional liquids powders bars and other food products wherein the resulting nutritional products are physically stable over shelf life and provide favorable organoleptic ...

A/B

Engineered multivalent and multispecific binding proteins methods of making and their uses in the prevention diagnosis and/or treatment of disease are provided.

Disclosed are nutritional compositions , and methods of using and making the nutritional compositions , that include calcium beta- hydroxy -beta- methylbutyrate and protein. The calcium beta -hydroxy- beta- methylbutyrate is in sequestered or ion -exchanged form to reduce the interaction of the calcium with the prot...

The present disclosure is directed to a nutritional powder , a translucent reconstitutable beverage formed therefrom, and methods relating thereto. The nutritional powder and beverage are adapted to include the proper balance of proteins , lipids , carbohydrates, vitamins and minerals appropriate for a pregnant woma...

The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts thereof, pro-drugs thereof, biologically active metabolites thereof, isomers thereof or stereoisomers thereof wherein the variables are as defined herein. The compounds of Formula (I) are useful as chemokine recept...

Extruded nutritional powders and methods of manufacturing the extruded nutritional powders , including extruded infant nutritional powders and extruded adult nutritional powders are provided. The processes utilize an extruder that is capable of internally mixing and emulsifying protein, and optionally , a carbohydra...

Disclosed are shelf stable concentrated liquid human milk fortifiers including extensively hydrolyzed casein. The long term shelf stable concentrated liquid human milk fortifiers include octenyl succinic acid (OSA) modified waxy potato starch as a stabilizer.

Nutritional products with improved organoleptic properties are provided herein. The general inventive concepts provide liquid nutritional products with improved viscosities while providing relatively higher levels of protein. In certain exemplary embodiments, the liquid nutritional products further provide beta -hyd...

N-[4-(3-Amino-1 H-indazol-4-yl)phenyl]-N"-(2-fluoro-5-methylphenyl)urea ¼ Ethanolate Crystalline Form 1, ways to make it, formulations comprising it and made with it and methods of treating patients having disease using it is disclosed.

The present invention features improved in vitro RNA display libraries to allow reliable expression and selection of scFv antibody molecules from expression libraries. The scFv antibody libraries of the invention contain an optimized, shortened inter-domain linker that improves expression scFv antibody expression. T...

A drinking container and its components are described. A cap for the baby bottle includes a reservoir for storage of a dry powder formula. A clamp ring locking indicator for a container is described. The locking indicator indicates when the clamp ring is correctly engaged to the container. A clamp ring also threads ...

N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N"-(2-fluoro-5-methylphenyl)urea    Tolueneate Crystalline Form 1, ways to make it and ways to use it are disclosed.

N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N"-(2-fluoro-5-methylphenyl)urea Crystalline Form 2, ways to make it, formulations comprising it and made with it and methods of treating patients having disease using it are disclosed.

DRYBLENDED NUTRITIONAL POWDERS Disclosed are reconstitutable nutritional powders comprising carbohydrate  protein  and lipid wherein at least one carbohydrate  such as lactose  and powdered lecithin have been dryblended into the reconstitutable nutritional powders. Also disclosed are methods of manufacturing a rec...

A cap for use in enteral feeding from a container. The cap includes a base and an insert cutter. The base has a top surface a bottom surface and an outer ring. The top surface has a protruding port suitable for insertion of a spike connector. The protruding port defines a spike insertion chamber extending from a spi...

Disclosed are concentrated liquid human milk fortifiers including extensively hydrolyzed casein and a stabilizer system. The stabilizer system includes an OSA modified corn starch in combination with a low acyl gellan gum. In one embodiment the concentrated liquid human milk fortifier is hypoallergenic and includes ...

Described herein are methods for isolating and purifying antibodies from a sample matrix. One aspect of the present disclosure is directed to viral reduction/inactivation of samples generated in the various steps of antibody purification. In a particular aspect, methods herein employ an acidification step followed b...

Anti-IL-18 antibodies are disclosed herein, including antigen-binding portions thereof. One or more methods for isolating and purifying anti-IL-18 antibodies from a sample matrix is presented. These isolated anti-IL-18 antibodies can be used in a clinical setting as well as in research and development. Pharmaceutica...

Embodiments of the invention relate to vector constructs and methods for expression of polypeptides including multimeric products such as therapeutic antibodies. Particular constructs allow for the generation of expression products from a single open reading frame (sORF). An embodiment provides an isolated or purifi...

Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 me...

A method of producing an emulsion and an extrudate for a powdered nutritional product is provided. The method includes utilizing an extruder (10) that contains a high shear element (32) positioned within the barrel of the extruder (20). The use of a high shear element (32) positioned within the barrel of the extrude...

Disclosed are concentrated liquid human milk fortifiers including extensively hydrolyzed casein and optionally a probiotic. The concentrated liquid human milk fortifier has a low water activity and a low pH thereby reducing microbial growth in the fortifier.

Packaging (10) includes a container (12) a bag (14) disposed in an interior cavity (36) of the outer container and a quantity of powdered beverage (16) in an interior space of the bag. The container may be sized and shaped to be held in a hand of a person. The container may have an interior surface that tapers towar...

Anti-IL-12 antibodies are disclosed herein, including antigen-binding portions thereof. One or more methods for isolating and purifying anti-IL-12 antibodies from a sample matrix is presented. These isolated anti-IL-12 antibodies can be used in a clinical setting as well as in research and development. Pharmaceutica...

Disclosed embodiments provide low viscosity, high caloric density liquid nutritional compositions. The use of non micellar milk protein in combination with hydrolyzed caseinate and unique formulation methods allow for improved organoleptic qualities and the production of liquid nutritional compositions displaying lo...

The present application relates to calcium channel inhibitors containing compounds of formula (I), wherein L1, L2, R1, R2, and R3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds ...

THE PRESENT DISCLOSURE PROVIDES METHODS FOR IDENTIFYING EARLY STAGE NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS WHO WILL HAVE AN UNFAVORABLE PROGNOSIS FOR THE RECURRENCE OF LUNG CANCER AFTER SURGICAL RESECTION. THE METHODS ARE BASED IN PART ON THE DISCOVERY OF CHROMOSOMAL COPY NUMBER ABNORMALITIES THAT CAN BE USED F...

The present disclosure is directed to a combination of carbohydrates (a slow rate of digestion simple carbohydrate a complex carbohydrate a nonabsorbent carbohydrate and an indigestible oligosaccharide) for use in a method of treating a pregnant woman wherein the method results in an improvement in the health of the...

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compovmds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

The present invention is directed to concentrated liquid human milk fortifiers using extensively hydrolyzed casein as a protein source a stabilizer system comprising octenyl succinic anhydride modified corn starch in combination with a low acyl gellan gum and the carotenoid lutein.

The invention relates to biaryl substituted azabicyclic alkane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

The present disclosure relates to soy protein-based powdered nutritional formulas  such as infant or toddler formulas  that contain lutein and fructooligosaccharide (FOS). The FOS stabilizes lutein present in the formula  resulting in less lutein degradation over the shelf-life of the formula. When fed to infants  t...

Disclosed are substantially stable sterilized liquid protein supplements including a highly soluble protein source for use with human milk and other infant or adult feeding formulas. The sterilized liquid protein supplements have a more neutral pH thereby inhibiting protein denaturation and reducing microbial growth...

The invention provides an aqueous formulation comprising water anp a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are for...

Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to individuals including preterm infants infants toddlers and children for improving gastrointestinal function and tolerance as well as the growth of beneficial microbiota. Suitable additional methods of using the n...

Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants infants toddlers and children for improving tolerance digestion and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis colic and short bowel syndrome. The predigested fats in...

Disclosed are nutritional formulas generally and infant formulas specifically including a combination of RRR-alpha tocopherol LC-PUFAs and optionally vitamin C. The combination enhances brain development and improves cognitive performance in an individual and specifically in an infant.

A method of reducing a pathogenic microorganism population in a powdered nutritional food composition is described herein. The powdered nutritional food composition includes a fat a protein and a carbohydrate. The method includes forming an emulsion of the powdered nutritional food composition and extruding the emul...

Disclosed are nutritional compositions generally and infant formulas specifically that include a combination of RRR alpha tocopherol fat and protein. The amount of non RRR alpha tocopherol stereoisomers in the nutritional compositions is limited. Also disclosed are methods of using the compositions to improve cognit...

Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions of compounds of formula (I), methods for using such compounds and compositions, and a process for preparing the compounds. ...

Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants term infants toddlers and children for reducing inflammation and the incidence of inflammatory diseases. ...

Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant toddler or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammat...

Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to preterm infants term infants toddlers and children for improving airway defense mechanisms.

The present disclosure is directed to low calorie infant formulas and in particular low calorie infant formulas that have a low buffering capacity exhibit an increased rate of protein hydrolysis and digestion and have an improved tolerance as compared to full calorie infant formulas. Also disclosed are low calorie l...

Disclosed are methods utilizing beta hydroxy beta methylbutyrate (HMB) for facilitating the recovery of muscle after a period of muscle disuse. The HMB facilitates the recovery of muscle mass in an individual and can also be used to prevent further muscle atrophy typically associated with muscle reloading after exte...

Disclosed are methods of reducing the incidence of oxidative stress in infants toddlers and children using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective at reducing inflammation and the incidence of inflammatory di...

Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to individuals including preterm infants infants toddlers and children for improving gastrointestinal function and tolerance as well as the growth of beneficial bacteria. Additional suitable methods of using the nut...

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Disclosed are nutritional emulsions comprising fat, protein and carbohydrate. The emulsions include a V-complex or aqueous phase comprising a food grade surfactant complexed with a polydextrose having an average degree of polymerization of at least about 10; wherein the nutritional emulsion has a first viscosity at ...

Disclosed are compositions comprising carbohydrate; lipid, comprising from about 0.25% to about 2.5 % lecithin by weight of total lipid; from about 90% to about 99.5% of intact protein by weight of total protein; and from about 0.5% to about 10% of at least one hydrolyzed protein selected from the group consisting o...

Disclosed are nutritional emulsions comprising fat carbohydrate protein and calcium HMB wherein soluble protein comprises from about 50% to 100% by weight of the total protein. Also disclosed are nutritional emulsions comprising fat carbohydrate protein and calcium HMB wherein soluble protein comprises from about 50...

The present disclosure relates to a combination of therapeutic agents for use in treating a patient suffering from cancer wherein said combination comprises at least one polyploidy inducing agent and at least one Bel  2 family protein inhibitor. In addition the present disclosure also relates to diagnostic assays us...

A container (10) for holding granular or powdered material. The container (10) includes walls a collar (14) a lid (16) and a latch (200). The walls define an interior space (26) and an upper portion the upper portion defining a sealing flange (30) and an opening to the interior space. The collar (14) is attached to ...

The present invention encompasses IL-1α binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Antibodies of the invention have high affinity for IL-1α and neutralize IL-1α activity. An antibody of the invention can be a full-length antibody or an...

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

DISCLOSED ARE NUTRITIONAL COMPOSITIONS COMPRISING A PEROXIDE-TREATED ASEPTIC PACKAGE AND A NUTRITIONAL LIQUID CONTAINED THEREIN, WHEREIN THE NUTRITIONAL LIQUID COMPRISES BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) AND AT LEAST ONE OF FAT, CARBOHYDRATE, AND PROTEIN. THE HMB PROVIDES A BUFFERING EFFECT IN THE NUTRITIONAL L...

Disclosed are shelf stable nutritional products including beta hydroxy beta methylbutyrate (HMB) and an oxidatively active species such as iron or copper. The HMB restricts the capacity of the oxidative species to catalyze the oxidation of nutrients such as fatty acids and vitamins thereby imparting both nutritional...

Disclosed are nutritional emulsions comprising fat, carbohydrate, protein, and calcium HMB, wherein the nutritional emulsion has a weight ratio of a soluble calcium binding capacity to soluble calcium of from about 2.3 to about 12.0. Also disclosed are nutritional emulsions comprising fat, carbohydrate, protein, and...

Disclosed are nutritional compositions comprising a plastic package and a nutritional liquid contained therein wherein the nutritional liquid comprises beta hydroxy beta methylbutyrate (HMB) and at least one of fat protein and carbohydrate. It has been found that HMB provides a buffering effect in the nutritional li...

Integrated devices that include a sample preparation component integrated with a detection component are disclosed. The sample preparation component may be a digital microfluidics module or a surface acoustic wave module which modules are used for combing a sample droplet with a reagent droplet and for performing...

Low calorie nutritional compositions comprising beta-hydroxy-beta-methylbutyric acid which may support accretion of lean body mass and development of a healthy body composition in term infants are provided. The low calorie nutritional compositions may be liquid or powder infant formulas.

Disclosed are nutritional compositions comprising agglomerated and/or co dried particles comprising a cereal beta glucan and a resistant starch. The agglomerated and/or co dried particles improve the cold water solubility of the nutritional compositions. The nutritional compositions may be dryblended powdered nutrit...

The present invention features solid compositions comprising amorphous Compound I. A solid dispersion of the present invention also contains a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant. Compound I may be formulated in an amorphous solid dispersion which comprises a ...

This invention is directed to the transformation of yeast, and mutants thereof, by electroporation, which result in stably transformed yeast host cells that express recombinant products. This invention also is directed to transformed yeast cells and libraries.

Disclosed are nutritional aqueous emulsions having high fiber content. These emulsions comprise fat, protein, and carbohydrate, which includes from 1.75% to about 4.0% by weight of diacylglycerol oil and from about 1.5% to about 9.0% by weight of fiber. These emulsions may also comprise fat, protein, and carbohydrat...

An orally deliverable pharmaceutical composition comprises a drug-carrier system having a Bcl-2 family protein inhibitory compound, e.g., ABT-263, in solution in a substantially non-aqueous carrier that comprises at least one phospholipid and a pharmaceutically acceptable solubilizing agent. The composition is suita...

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of us...

ABT-263 bis-HCl and crystalline polymorphs thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described . This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

The invention provides a method of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.

Disclosed is a method of making nutritional emulsions comprising: (A) heating and blending together an emulsifying agent having a melt point above about 25 C and oil having hydrophobic off notes (e.g. non encapsulated polyunsaturated fatty acid) in a weight ratio of at least about 1:15; (B) adding the heated blend t...

Disclosed are nutritional emulsions comprising fat protein and carbohydrate including from about 0.01% to about 5% by weight of an oil having hydrophobic off notes that is process encapsulated by an emulsifying agent having a melt point above about 25 C and maltodextrin having a DE of about 10 or less wherein the we...

Disclosed are nutritional products and nutritional bars having increased shelf life. The nutritional product or nutritional bar is manufactured utilizing high power ultrasound in combination with an extrusion process or slabbing process. It has been found that by utilizing high power ultrasound during the manufactur...

The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R1, R2, R3, R4, R5, A, Y1, Y2, and Y3 are as defined in the specifi...

/CHENP/2008/ ABSTRACT CYCLOPROPYL AMINE DERIVATIVES AS HISTAMIN H3 RECEPTOR MODULATORS histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands. methods for using such compounds and compositions, and a process for preparing compounds within the sc...

Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

A compound of the formula, or is disclosed as a prodrug of an HIV protease inhibitor. Methods and compositions or inhibiting HIV protease activity and treating HIV infection are also disclosed.

Methods of qualitatively and/or quantitatively detecting the presence of mutations modifications or impurities in a protein sample are provided. The methods utilize isotopically labeled variants of amino acids incorporated into proteins prior to protein digest to enable comparisons of two protein samples in bottom u...

Disclosed are methods of manufacturing powdered nutritional products including powdered infant formulas and powdered adult nutritional products using extrusion. The methods include utilizing ultrasonic energy in the extruder during manufacturing. The application of ultrasonic energy to the extruder allows the fat gl...

The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, metabolic syndrome , hyperinsulinemia, obesity, atherosclerosis, various immunomodulatory diseases, and other d...

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

A rapamycin analog composition includes a crystalline form of a rapamycin analog. The crystal can be a hydrate, dehydrate, solvate, or desolvate. The rapamycin analog can have a structure of Formula (I), which is optionally a prodrug, salt, derivative, or combination thereof: Formula (I)

A medical device comprising a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating conta...

A medical device comprising a supporting structure having a coating on the surface thereof, the coating containing a therapeutic substance, such as, for example, a drug. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, periphe...

N/A

N/A

Compounds of Formula (I), are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Method and compositions for providing glutamine supplementation to a human orally administering an effective amount of N-acetyl-I-glutamine or a nutritionally acceptable salt thereof. The N-acetyl L-glutamine or a nutritionally acceptable salt thereof can be incorporated into any liquid composition that is suitable ...

The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protei...

A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutical...

The present invention relates to antibodies and antibody fragments thereof that bind to and activate an erythropoietin receptor. The present invention also relates to methods of modulating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies as well as pharmaceutical compositions c...

N/A

The present invention provides an HCV polymerase inhibiting compound having the formula (I) and a composition comprising a therapeutically effective amount of said compound. The present invention also provides a method for inhibiting hepatitis C virus (HCV) polymerase, a method for inhibiting HCV viral replication, ...

An interventional device for delivery of multiple beneficial agents. The device includes a prosthesis having a surface loaded with a plurality of discrete droplets of first and second beneficial agents. The discrete droplets of beneficial agent are loaded along a first controlled trajectory and the second beneficial...

Compounds of formula (I), wherein A, R1 R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladder overactivity, urinary incontinence, and other disorders caused by or exacerbated by TRPV1. ...

The present invention features processes of making tablets having reduced internal fractures. In one aspect, the processes comprise the steps of (1) compressing a pre-tablatting material in a die to form a tablet, where an internal surface of the die is lubricated with at least one lubricant, and the pre-tabletting ...

The present invention discloses processes for the preparation and isolation of the individual stereoisomers of 1-amino, 3-substituted phenylcyclopentane-carboxylates.

The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.

Anti-Aß globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions compris¬ing said antibodies, uses of said antibodies and methods of using said antibodies. The present invention relates to anti-Aß globul...

Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor. ...

The present invention relates to stable amorphous 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-viny|-3-cephem-4-carboxylic acid (syn isomer), methods for its preparation, and pharmaceutical compositions comprising stable amorphous 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-3-cephem-4-carbox...

The present invention discloses a novel powder for oral suspension of cefdinir. Also disclosed are methods of preparing the suspension and methods of treatment using the suspension.

The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistanc...

Methods for identifying cancer patients eligible to receive Bcl-2 family inhibitor therapy and for monitoring patient response to Bcl-2 family inhibitor therapy comprise assessment of the expression levels of the biomarker combinations set out in TABLES 1, 2, 3, 4, 5 or 6 in a patient tissue sample. The methods of t...

Inhibitors  of poly(ADP-ribose)polymerase,  ways to  make  them  and methods of treating patients using them are disclosed.

The present invention relates to a method of treating an individual having a condition characterized by induced an imbalance in type 1 and type 2 cytokine levels, comprising administering to the individual an effective amount of β-hydroxy-β-methylbutyrate to modulate the imbalance in type 1 and type 2 cytokine produ...

Disclosed are nutritional compositions for treating rheumatic diseases. The nutritional compositions contain a fat source containing at least one of: 1) at least one omega-3 long chain polyunsaturated fatty acid and 2) at least one omega-6 long chain polyunsaturated fatty acid; a carbohydrate source; a protein sourc...

The present invention discloses compositions and a method of improving the pharmacokinetics of pharmaceutical agents (or pharmaceutically acceptable salts, esters, and prodrugs thereof) which are metaboilized by cytochrome P450 monoxygenase comprising coadministering ritonavir or a pharmaceutically acceptable salt, ...

A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.

The present invention relates to stable amorphous 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-3-cephem-4-carboxylic acid (syn isomer), methods for its preparation, and pharmaceutical compositions comprising stable amorphous 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-3-cephem-4-carbox...

The present invention relates to compounds of formula (I-VII) (I), or a pharmaceutically acceptable salt or prodrug thereof, in which A, L, R6, R7and R8 are defined herein. The present invention also relates to methods of trating pain using these compounds and pharmaceutical compositions including these compounds. ...

The present invention discloses novel compounds of general formula (I), or a pharmaceutically acceptable salt or prodrug thereof (in which X1 - X5, R5 - R8b, Z1 - Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and p...

Compounds having the formula: (I), are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

The present invention relates to binding proteins and, in particular, humanized antibodies that may be used, for example, in the diagnosis, treatment and prevention of Alzheimer"s Disease and related conditions.

The invention relates to octahydro-pyrrolo[3,4-b]pyrrole N-oxides as prodrugs of CNS-active compounds, compositions comprising such compounds, methods for making the compounds, salts, and polymorphs, and methods of treating conditions and disorders using such compounds and compositions. Octahydro-pyrrolo[3,4-b]pyrro...

Disclosed are useful constructs and methods for the expression of proteins using primary translation products that are processed within a recombinant host cell. Constructs comprising a single open reading frame (sORF) are described for protein expression including expression of multiple polypeptides. A primary trans...

The present invention encompasses IL- 13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-leng...

The present invention provides a modified release formulation comprising an active agent in a hydrophilic polymer matrix wherein the active agent is a salt of fenofibric acid wherein the release rate of the formulation in an in vitro dissolution is substantially independent of the ionic strength of the dissolution m...

A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutical...

Compounds of formula (I), or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Pharmaceutical compositions of formula (I) and related methods for treating or preventing metabolic diseases or conditions.

Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a b...

The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the...

Abstract PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE The invention relates to a composition comprising a neuronal nicotinic receptor ligand and an positive allosteric modulator, a method of using the same, and a related article of manufacture.

The present invention is directed to compounds of formula (I) (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.

Methods for treating mammals before, during and after cardiac arrest are disclosed. Pharmaceutical compositions comprising levosimendan useful for such treatment also are disclosed.

The instant invention provides processes and intermediates employed in the synthesis of ((2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2S-(1-tetrahydropyrimid-2-onyl)~3-methyl-butanoyl)amino-1,6-dipheny!hexane and analogs thereof.

The present invention discloses a novel powder for oral suspension of cefdinir. Also disclosed are methods of preparing the suspension and methods of treatment using the suspension.

A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.

The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor.

A single-step, one-pot process to obtain zotarolimus and other rapamycin derivatives on large scale that improves currently available syntheses. In one embodiment, dried rapamycin is dissolved in isopropylacetate . After cooling and 2,6-Lutidine addition, triflic anhydride is slowly added at -30° C. Salts are remove...

Disclosed are infant formulas and corresponding methods of using them to promote retinal health and vision development in infants. The formulas, which are free of egg phospholipids and comprise fat, protein, carbohydrate, vitamins, and minerals, including docosahexaenoic acid and, on a ready-to-feed basis, at least ...

Disclosed herein is a method for favorably modulating the health-related quality of life and the health-related quality-adjusted time-to-disease progression in a patient having prostate cancer and a method for measuring of the health-related quality-adjusted time-to-disease progression.

The invention relates to novel herbicidal synergistic compound combinations comprising on the one hand known N-aryl-triazoline(ethi)ones and on the other hand knownherbicidally active compounds and/or compounds which improve crop plant compatibility and which can be used with particularly good results for the select...

The present invention relates to a batch crystallization method for crystallizing anti-human TNFalpha (hTNFalpha) antibody and antibody fragments which allows the production of said antibody on an industrial scale; a method of controlling the size of antibody crystals, for example, crystals of anti-hTNFalpha antibod...

N/A

N-[4-(3-Amino-1 H-indazol-4-yl)phenyl]-N"-(2-fluoro-6-methylphenyl)urea Hydrate Crystalline Form 1, ways to make it, formulations comprising it and made with it and methods of treating patients having disease using it are disclosed.

N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N"-(2-fluoro-5-methylphenyl)urea Crystalline Form 1, ways to make it, formulations comprising it and made with it and methods of treating patients having disease using it are disclosed.

2-((R)-2-Methylpyrrolidin-2-yl)-1 H-benzimidazole-4-carboxamide Crystalline Form 1, ways to make it, compositions comprising it and made using it, and methods of treating patients having disease using it are disclosed.

The present invention relates to an induced viscosity nutritional emulsion comprising (A) protein having a protein-bound methionine sulfoxide content that is 8% or less of the total protein-bound methionine, on a molar basis, (3} fat, and (C) an induced viscosity fiber system that provides the emulsion with a packag...

Disclosed are compositions comprising carbohydrate; lipid, comprising from about 0.25% to about 2.5 % lecithin by weight of total lipid; from about 0.5% to about 10% hydrolyzed casein protein by weight of total protein; and from about 90% to about 99.5% intact protein by weight of total protein; wherein the composit...

The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction

The present invention provides a pharmaceutical dosage formulation, and more particularly, to a pharmaceutical dosage formulation comprising an HIV protease inhibitor.

Octahydro-pyrrolo[3,4-b]pyrrole derivatives or a pharmaceutically acceptable salt, ester, amide, prodrug, or radiolabeled form thereof, wherein R1 is alkyl, C3-C5 cycloalkyl. or (C3-C5 cycloalkyl)methyl; R2a, R2b, R2c, R2d, R2e, and R2f each are independently hydrogen, methyl, or fluoromethyl; R3a, R3b, R3c, and R3d...

Compounds of Formula (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of treatment comprising compounds of Formula (I), and methods of inhibiting the PARP enzyme comprising...

Compounds which inhibit the activity of anti-apoptotic family protein members, compositions containing the compounds and methods of treating diseases during which occur expression one or more than one of an anti?apoptotic family protein member are disclosed.

Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for il-1 alpha and il-1 beta and neutralize il-1 alpha and i...

The invention relates to novel amide derivatives that are PAMs of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such pompounds and compositions.

The present invention relates to compounds of formula (I-VII) (I), or a pharmaceutically acceptable salt or prodrug thereof, in which A, L, R6, R7and R8 are defined herein. The present invention also relates to methods of trating pain using these compounds and pharmaceutical compositions including these compounds. ...

The invention relates to a series of substituted pyrrole derivatives, compositions comprising the same, and methods of treating conditions and disorders using such compounds and compositions.

The present invention relates to a process of preparing indazolyl ureas that are useful as antagonists of the vanilloid receptor subtype 1 (VR1).

A class of substituted β-amino acids are potent inhibitors of methionine aminopeptidase type 2 (MetAP2) and are thus useful in inhibiting angiogenesis and disease conditions which depend upon angiogenesis for their development such as diabetic retinopathy, tumor growth, and conditions of inflammation. Pharmaceutical...

N/A

The present invention relates to antibodies and antibody fragments thereof that bind to and activate an erythropoietin receptor. The present invention also relates to methods of modulating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies as well as pharmaceutical compositions ...

The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor.

The present invention discloses novel compounds of general formula (I), or a pharmaceutically acceptable salt or prodrug thereof (in which X1 - X5, R5 - R8b, Z1 - Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and p...

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+-O"; X is O, S, -NH-, and -N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by &agr;7 nAChR ligands. Also disclosed are pharmaceuti...

The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in v...

The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entircly human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vi...

Processes to make compounds, including N-acylsulfonamide apoptosis promoters are disclosed.

Disclosed are infant formulas comprising, on an as-fed basis (A) at ieast about 5 mg/L of gangiioskfes, (B) at least about 150 mg/L of phospholipids, (C) Jactoferrin, and (D) at (east about 70 mg/L of sialic acid, with at feast about 2.5% by weight of the sialic acid as lipid-bound sialic acid. From about 50% to 100...

Disclosed are infant formulas comprising at least about 6.5 g/L, on an as-fed basis, of an enriched whey protein concentrate, at least about 0.13% docosahexaenoic acid by weight of total fatty acids, and at least about 0.25% arachidonic acid by weight of total fatty acids. The formulas also typically include at leas...

N/A

N/A

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.

The present invention relates to the salt (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate and to methods of preparing the salt.

Disclosed are nutritional compositions and methods of using the compositions for treating or preventing osteoporosis. The compositions comprise (A) those dried fruit solids that inherently comprise flavonoids, hydroxycinnamic acids, and a fiber component of which at least about 20% by weight is soluble fiber, and (B...

The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor.

A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.

N/A

New crystalline forms of lopinavir are disclosed.

N/A

Disclosed are compositions, including low-calorie beverages or liquids, comprising isoleucine, leucine, valine, cysteine, and methionine, in specified amounts, weight ratios, or both. The compositions are especially useful in treating individuals afflicted with impaired glucose tolerance or diabetes. ...

Heterocyclic substituted aminoazacyclic compounds of the formula (I): Z-R3, wherein Z is a defined aminoazacycle and R3 is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.

Disclosed are nutritional emulsions comprising fat, protein, and carbohydrate, including: (A) an induced viscosity fiber system, and (B) a V-complex located within an aqueous phase of the emulsion and comprising a food grade surfactant complexed with a polydextrose having an average degree of polymerization of at le...

The present invention is directed to compounds of formula (I), wherein variables X1, X2, Y, R1a, R1b, R2a, R2b, A1, A2, A3, and A4 are as defined in the description, and methods of use to treat pain, neuropathic pain, allodynia, pain associated with inflammation or an inflammatory disease, inflammatory hyperalgesia,...

The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/o...

ABSTRACT The invention relates to fused bicycloheterocycle substituted azabicyclic alkane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

The present invention relates to engineered multivalent and multispecific binding proteins, Methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

The invention provides a compound of Formula (I), pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions. ...

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

The invention relates to neuronal nicotinic receptor ligands, methods of identifying such ligands for neuronal nicotinic receptor modulation, particularly such ligands demonstrating beneficial side effect toierability, and methods of using such neuronal nicotinic receptor ligands to provide pharmaceutical compositi...

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Disclosed are compounds that are agonists or antagonists of the S1P5 receptor, compositions comprising said compounds, and methods of using said compounds and compositions. In certain embodiments, said compounds are l-benzylazetidine-3-carboxylic acid derivatives. In certain embodiments, said methods relate to the t...

Proteins that bind IL-17 and/or IL- 17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL- 17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.

An enteral connector assembly and system (700) communicates fluid between a bag B' or a bottle B" and an enteral feeding set. The system (700) includes an end cap (705) that communicates enteral fluid across a barrier (715) having a specially configured barrier key way (720) formed with a barrier port (725). The bar...

The present invention relates to compounds of formula (I): wherein R1, R2, and R3, are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.

The present invention relates to compounds of formula (I): wherein Q, G1, G2, and G3, are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.

The present invention relates to novel macrocyclic compounds and methods of use thereof. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically ac...

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound, e.g., ABT-263, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for prep...

A liquid pharmaceutical composition comprises an aqueous medium having suspended therein a solid particulate Bcl-2 family protein inhibitory compound such as ABT-263, having a D90 particle size not greater than about 3 µm; wherein the aqueous medium further comprises at least one pharmaceutically acceptable surfacta...

The present disclosure relates to isolated polynucleotides encoding a delta 9-elongase, delta 9-elongases encoded by the isolated polynucleotides, expression vectors comprising the isolated polynucleotides, host cells comprising the expression vectors, and methods for producing delta 9-elongase and polyunsaturated f...

The instant invention relates to the field of protein production, and in particular is relates to compositions and processes for improving the production levels of recombinant proteins expressed in host cells.

Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2- ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 ...

A bottle packaging ( 10 ) includes a groove ( 40 ) on the neck ( 22 ) of a bottle with the groove spaced longitudinally from a shoulder of the bottle ( 11 ) a distance greater than or equal to a width of the groove and upper ( 22a) and lower ( 22b) portions of the neck may have outer transverse cross  sectional dime...

The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance...

Compounds of Formula (I) (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of treatment comprising compounds of Formula (I), and methods of inhibiting the PARP enzyme compri...

The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid. ...

Disclosed are substantially clear nutritional liquids comprising protein and calcium HMB wherein soluble protein represents from about 65% to 100% by weight of total protein. The liquids have a pH of from about 2.8 to about 4.6 and may be manufactured as a hot fill product. The substantially clear nutritional liquid...

Engineered multivalent and multispecific binding proteins methods of making and their uses in the prevention diagnosis and/or treatment of disease are provided.

Disclosed are nutritional products comprising calcium beta hydroxy beta methylbutyrate conjugated linoleic acid and protein. The nutritional product forms include nutritional liquids and nutritional powders. The nutritional products not only provide benefits for individuals concerned with muscle health and functiona...

Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants infants toddlers and children for improving tolerance digestion and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis colic and short bowel syndrome. The predigested fats in...

Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants infants toddlers and children for improving tolerance digestion and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis colic and short bowel syndrome. The predigested fats in...

Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to preterm infants term infants toddlers and children for reducing inflammation and the incidence of inflammatory diseases.

The present disclosure is directed to low calorie infant formulas and in particular low calorie infant formulas that have a low buffering capacity exhibit an increased rate of protein hydrolysis and digestion and have an improved tolerance as compared to full calorie infant formulas. Also disclosed are low calorie l...

Disclosed are nutritional compositions including human milk oligosaccharides and nucleotides that can be administered to preterm infants term infants toddlers and children for reducing inflammation and the incidence of inflammatory diseases.

Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1α and IL-1β and neutralize IL-1α and IL-1 β activity...

A single use pouch (10) for liquid product has a front panel (12) and a back panel (14). The front and back panels at least in part cooperatively define an interior space (15) of the pouch. The interior space has a total liquid capacity. A volume of liquid product is contained within the interior space. The volume o...

Improved pharmaceutical compositions are provided comprising one or more HIV protease inhibiting compounds having improved dissolution properties in a mixture of a fatty acid, ethanol, and water.

The present invention relates to a lipid system, and methods for using such a lipid system, containing specific relative ratios of omega-3, omega-6, and omega-9 fatty acids. The lipid system may be used independently or as a component of a nutritional product. A lipid system according to the present invention may co...

Enantiomerically enriched compounds having the absolute stereochemistry of the formula (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, which are useful for inhibiting neuraminidases from disease-causing microorganisms, especially, influenza neuraminidase. Also disclosed are compositions and meth...

A process for the conversion of an N-hydroxylamine to an N-hydeoxyformamide comprising reacting the N-hydroxylamine with 2,2,2-trifluoroethylformate in an optionally buffered solvent.

The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 -lsTSpecifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for ML-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An ...

Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+-O-; X is O, S, -NH-, and -N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by a7 nAChR ligands. Also disclosed are pharmaceutical ...

The present invention relates to trihemihydrate, novel lower hydrate and anhydrate forms of 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-3-cephem-4-carboxylic acid (syn isomer), methods for their preparation, and pharmaceutical compositions comprising these forms.

(0101) Disclosed are nutritional aqueous emulsions having high fiber content. An aqueous emulsion comprising fat, protein, and carbohydrate, which includes from about 0.5% to about 9.0% by weight of a milk protein concentrate; from about 2.0% to about 6.0% by weight of glycerin, from about 2.3% to about 9.0% by weig...

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of us...

Compositions and methods comprising recombinant expression vector elements (rEVEs) to enhance the level of expression of recombinant proteins are described. Other compositions and methods for lowering, substantially suppressing, or essentially silencing expression of a recombinant protein are also described. ...

Preterm infant nutritional compositions comprising beta- hydroxy- beta- methylbutyric acid for supporting growth , accretion of lean body mass , and a healthy body composition in preterm infants are provided. The preterm infant nutritional compositions may be liquid formulas , fortifiers , and supplements. Methods f...

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

This invention relates to a method of improving CNS maturation in an infant by administering a mixture of natural tocopherols, wherein the composition contains an optimum tocopherol profile similar to that found in human breast milk, and can encompass a tocopherol profile from early stage to transitional to mature...

Methods and apparatus for improving measurements of cardiovascular health status in a given individual are provided. The comprehensive assessment of cardiovascular health includes at least two components: risk factor assessment based on epidemiologic studies and functional status of the individual. Structural studie...

The present invention encompasses prostaglandin ET (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the inven...

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of us...

Disclosed are prenatal and lactation supplements for pregnant women and lactating women, which include a combination of RRR-alpha-tocopherol, docosahexaenoic acid (DHA), trans-lutein, phospholipids, and at least one nuclear receptor activating ligand other than RRR-alpha-tocopherol, DHA, and translutein. The supplem...

A bottle for storing liquid nutrition and feeding liquid nutrition to an infant. The bottle includes a base portion, a neck portion for removably securing a cap or nipple, and a body portion disposed between the base portion and the neck portion. A rib protrudes from an outer surface of the bottle and is arranged fo...

An interventional device for delivery of beneficial agent to a lumen and methods of loading and manufacture of the same, which include a prosthesis loaded with beneficial agent to provide a controlled dosage concentration of beneficial agent to the lumen. The beneficial agent is loaded onto the prosthesis by a fluid...

A product package for storing nutritional or pharmaceutical products includes a container having a body and an opening a seal (300 600) applied to the container to seal the opening and a closure removably engaged with the container to selectively close the opening of the container. The closure and/or the seal includ...

Disclosed are powdered nutritional formulations comprising at least one plant protein such as pea protein wherein at least a portion of the plant protein has been spray dried and dry blended into the nutritional formulation. The liquids derived from reconstituting the powdered nutritional formulations exhibit little...

The present invention features improved methods of in vitro RNA display to allow reliable expression and selection of scFv antibody molecules from expression libraries. The improved methods, in part, involve the use of mildly reducing conditions, which favor of scFv intra-chain disulphide bond and thus correct foldi...

An apparatus includes a bottle a cap and a tamper evident film. The bottle forms an opening having a lip that extends circumferentially around the opening. The cap is able to cover and seal the opening. The cap has a top with an outer surface an inner surface and a side wall. The outer surface and the side wall defi...

Disclosed are nutritional aqueous emulsions having high fiber content. These emulsions comprise fat, protein, and carbohydrate, including (a) from 1.75% to about 4.0% by weight of a diacylglycerol oil; (b) from about 0.5% to about 9.0% by weight of a milk protein concentrate; (c) from about 2.0% to about 9.0% by wei...

Methods of Preventing or treating arthritis is disclosed

Disclosed are nutritional compositions and methods for preparing the compositions, comprising fat, protein, and carbohydrate, including a combination of curcumin, demethoxycurcumin, and bisdemethoxycurcumin, which combination is solubilized in a polar oil having an HLB value of from about 0.7 to about 14 wherein the...

Disclosed are stabilized liquid nutritional compositions including stabilized infant formulas which comprise a first insoluble calcium salt a second insoluble calcium salt and an emulsifier. The first insoluble calcium salt and the second insoluble calcium salt have different average particle sizes. The stabilized n...

Disclosed are stabilized nutritional compositions having a stabilizer system including starch or a combination of starch and maltotriose and methods for manufacturing the compositions. The retrogradation effect commonly seen with starch stabilizers is substantially reduced or even eliminated in the disclosed nutriti...

Disclosed are methods for enhancing neural function in an individual such as an older adult. The methods include administering nutritional compositions comprising HMB to the individual. The nutritional compositions provide benefits for individuals that have or may be at risk of having cognitive decline cognitive imp...

The invention relates to batch crystallization methods for crystallizing an anti-hlL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions. ...

An orally deliverable pharmaceutical composition comprises a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administ...

The Invention provides a method of treating psoriasis in a subject by administering to a Subject an antibody capable of binding to the p40 subunit of IL- 12 and /or IL-23

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

Disclosed herein are cannabinoid receptor ligands of formula (I) wherein A1, A5, Rx, X4, and z are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

N/A

The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistanc...

Compounds of formula (I) Z-Ar₁ -Ar₂ wherein Z is a diazabicyclic amine, Ar₁ is a 5- or 6-membered aromatic ring, and Ar₂ is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbaz...

N/A

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.

ABSTRACT' EV/PCT/2001/01040/CHE"A cinnamide compound having cell adhesion anti-inflammatory and immunesuppressive properties"The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions containing th...

The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune reponse in a mammal.

A medical device comprising:An interventional component to be deployed in a patient; a beneficial agent to be delivered from the interventional component, the beneficial agent loaded on at least a portion of the interventional component and having a first LogP value; and an effective amount of a hydrat...

Compounds effective in inhibiting replication of Hepatitis C virus ('HCV') or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the ...

Compounds effective in inhibiting replication of Hepatitis C virus ("IICV") or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for th...

Compounds of formula (I) which inhibit the activity of anti-apoptotic Mcl-I protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl-I protein are disclosed.

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of us...

The invention relates to compounds that are vitamin D receptor activators, compositions comprising such compounds, methods of Using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes

The present application relates to calcium channel inhibitors comprising compounds of formula (I), formula (II), formula (III), or formula (IV), wherein L1, R1, R2, R3, R4, R5, R6, R7 and Rc are as defined in the specification. The present application also relates to compositions comprising such compounds, and meth...

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

The present invention is related to isolated polynucleotides encoding a delta-8 desaturase, delta-8 desaturases encoded by the isolated polynucleotides, expression vectors containing the isolated polynucleotides, host cells containing the expression vectors and methods for producing delta-8 desaturases and polyunsat...

The invention provides compositions and methods for Inhibiting fractionation of immunoglobulins comprising a lambda light chain based on the observation that iron, in the presence of histidine, results in increased fragmentation of a recombinant fully human IgG molecule containing a lambda light chain due to cleavag...

The present invention relates to engineered multivalent and multispecific Minding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

This invention is directed to: (a) processes for preparing a compound and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compound and salts; (c) pharmaceutical compositions comprising the compound or salts; and (d) methods of use...

Disclosed are nutritional powders comprising HMB and at least one of fat  carbohydrate  protein  wherein the HMB is spray dried with at least a portion of at least one of the fat  protein  and carbohydrate in the composition. Also disclosed is a method for making such powders comprising 1) preparing a liquid slurry ...

Anti-viral compounds effective in inhibiting replication of Hepatitis C virus ("HCV").

A nutritional supplement powder and method of supplementing the nutritional value of a food or beverage is provided. The nutritional supplement powder includes a protein system vitamins minerals and fiber. The protein system has a water solubility of at least about 70% at room temperature. The nutritional supplement...

A nutritional composition including an oxidizable component and a water soluble plant extract is provided. The water soluble plant extract includes rosmarinic acid and has a total phenolic content such that a ratio of the total phenolic content to the rosmarinic acid is between about 1.1:1 to about 3.5:1. A method o...

Whey protein based liquid nutritional compositions are provided. The liquid nutritional compositions include at least 7% by weight protein and all of the protein is provided by a whey protein hydrolysate and an intact whey protein. The liquid nutritional compositions have a neutral pH a low viscosity and are shelf s...

Liquid nutritional compositions including both soy protein and dairy protein demonstrate enhanced rheological properties. By suitable selection of the types and amounts of these proteins high caloric density products can be obtained without adversely affecting other desirable properties such as nutritional value sta...

Integrated devices that include a sample preparation component integrated with a detection component are disclosed. The sample preparation component may be a digital microfluidics module or a surface acoustic wave module which modules are used for combing a sample droplet with a reagent droplet and for performing ad...

Methods devices and systems for analyte analysis using a nanopore are disclosed. The methods devices and systems utilize a first and a second binding member that each specifically bind to an analyte in a biological sample. The method further includes detecting and/or counting a cleavable tag attached to the second b...

Compounds having the formula (I) are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as...

Potato protein in combination with other vegetable proteins replaces a portion of the total protein in a nutrition drink or shake or other nutritional composition intended for oral consumption. By suitable selection of the types and amounts of these proteins the overall cost of manufacturing the nutritional composit...

The present invention relates to a pharmaceutical or nutritional combination comprising beta-hydroxy beta-methylbutyrate (HMB) and tetrahydrocurcumin (THC) and methods comprising administering the combination to a subject. The methods of the invention relate to attenuating muscle protein degradation and/or preservin...

Systems and methods for onboard pooling of samples for high-throughput analysis of the samples. Including a sample loading area for receiving a plurality of sample tubes, and a sample transport configured to continually transport individual vessels along a transport path from a sample dispense position to a sample c...

The presently disclosed subject matter relates to methods for rapid, sensitive, and high-throughput nucleic acid testing of biological samples, e.g., blood, serum, or plasma samples from donors, as well as systems capable of performing such high-throughput nucleic acid testing.

Disclosed herein are methods and systems for determining whether at least one indeterminate pulmonary nodule identified in a subject is likely to be malignant or likely not to be malignant.